Terns Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TERN, updated each market day.
TERN AI Sentiment
AI predicts Terns Pharmaceuticals, Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Terns Pharmaceuticals, Inc. Common Stock
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The company is seeking strategic partners to advance the TERN-501 and TERN-801 programs.
Sector
Exchange
Market Cap
$6,066,127,883
Cap Tier
Employees
59
Headquarters
FOSTER CITY, CA
Listed Since
Feb. 5, 2021
Website
TERN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TERN Volatility
Terns Pharmaceuticals, Inc. Common Stock has shown low price volatility over the last 5 trading days. Low volatility suggests steady price action with smaller daily moves.
